Assignee
EFFECTOR THERAPEUTICS INC
US·21 granted patents·17 pending applications·67 citations·filing 2015–2023
Top patents by PatentIndex Score
38 records- 0195US9382248B2Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2015·Granted Jul 5, 2016·14 cites·25 claims
- 0294US9669031B2MNK inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2016·Granted Jun 6, 2017·12 cites·20 claims
- 0389US9814718B2MNK inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2017·Granted Nov 14, 2017·5 cites·20 claims
- 0488US11083727B2Piperidine-substituted Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2018·Granted Aug 10, 2021·2 cites·3 claims
- 0588US10577378B2EIF4A-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2018·Granted Mar 3, 2020·6 cites·14 claims
- 0688US9957277B2eIF4A-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2016·Granted May 1, 2018·6 cites·14 claims
- 0785US11130757B2Crystalline forms of MNK inhibitorsEFFECTOR THERAPEUTICS INC·Filed 2019·Granted Sep 28, 2021·2 cites·10 claims
- 0885US10000487B2Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancersEFFECTOR THERAPEUTICS INC·Filed 2016·Granted Jun 19, 2018·5 cites·5 claims
- 0983US11440917B2EIF4A-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2020·Granted Sep 13, 2022·1 cites·19 claims
- 1082US9993494B2Compositions and methods for treating fibrotic diseaseEFFECTOR THERAPEUTICS INC·Filed 2015·Granted Jun 12, 2018·6 cites·8 claims
- 1182US2023295179A1Eif4a-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1280US10780119B2Methods and compositions for cellular immunotherapyEFFECTOR THERAPEUTICS INC·Filed 2018·Granted Sep 22, 2020·1 cites·10 claims
- 1380US10112955B2Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2EFFECTOR THERAPEUTICS INC·Filed 2016·Granted Oct 30, 2018·2 cites·19 claims
- 1479US11286268B1EIF4E-inhibiting compounds and methodsEFFECTOR THERAPEUTICS INC·Filed 2020·Granted Mar 29, 2022·1 cites·28 claims
- 1578US10793551B2Benzimidazole-indole inhibitors of Mnk1 and Mnk2EFFECTOR THERAPEUTICS INC·Filed 2018·Granted Oct 6, 2020·2 cites·16 claims
- 1678US10702526B2Inhibitors of immune checkpoint modulators and related methodsEFFECTOR THERAPEUTICS INC·Filed 2016·Granted Jul 7, 2020·2 cites·23 claims
- 1777US2023071483A1Eif4a-inhibiting compounds and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1875US2021338673A1Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1974US11878015B2Piperidine-substituted Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2021·Granted Jan 23, 2024·0 cites·9 claims
- 2073US2023381232A1Methods and compositions for cellular immunotherapyEFFECTOR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2170US11952375B2Crystalline forms of Mnk inhibitorsEFFECTOR THERAPEUTICS INC·Filed 2021·Granted Apr 9, 2024·0 cites·6 claims
- 2269US11564947B2Methods and compositions for cellular immunotherapyEFFECTOR THERAPEUTICS INC·Filed 2020·Granted Jan 31, 2023·0 cites·20 claims
- 2366US2019209560A1Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 2463US2018085368A1Mnk inhibitors and methods related theretoEFFECTOR THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 2563US2023108594A1Eif4e-inhibiting compounds and methodsEFFECTOR THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2662US11014926B2Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2EFFECTOR THERAPEUTICS INC·Filed 2019·Granted May 25, 2021·0 cites·17 claims
- 2759US2021010086A1Mnk biomarkers and uses thereofEFFECTOR THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2857US2021046074A1Inhibitors of immune checkpoint modulators and related methodsEFFECTOR THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2957US2025243221A1Covalent modifiers of eif4e inhibiting compoundsEFFECTOR THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3056US2019152988A1Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2EFFECTOR THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3155US2018228803A1Piperidine-Substituted Mnk Inhibitors and Methods Related TheretoEFFECTOR THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3252US10576098B2Compositions and methods for treating fibrotic diseaseEFFECTOR THERAPEUTICS INC·Filed 2018·Granted Mar 3, 2020·0 cites·9 claims
- 3352US2017191136A1Mnk biomarkers and uses thereofEFFECTOR THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3451US2022378821A1Methods of treating braf-mutated cancer cellsEFFECTOR THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3551US2021299111A1Eif4a inhibitor combinationsEFFECTOR THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3646US2017121339A1Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2EFFECTOR THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3745US11576933B2Compositions and methods for an improved antitumor immune responseEFFECTOR THERAPEUTICS INC·Filed 2018·Granted Feb 14, 2023·0 cites·16 claims
- 3830US2017247692A1Compositions and methods for treating neurological disordersEFFECTOR THERAPEUTICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EFFECTOR THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →